Prosight Management, LP Cara Therapeutics, Inc. Transaction History

Prosight Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$12.38 - $29.19 $1.24 Million - $2.92 Million	-100,000 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$15.07 - $21.71 $2.92 Million - $4.21 Million	-194,041 Reduced 65.99%	100,000 $2.17 Million
Q4 2020 Feb 12, 2021	BUY	$12.72 - $16.16 $1.52 Million - $1.93 Million	119,397 Added 68.37%	294,041 $4.45 Million
Q3 2020 Nov 13, 2020	BUY	$12.34 - $17.92 $1.08 Million - $1.57 Million	87,679 Added 100.82%	174,644 $2.22 Million
Q2 2020 Aug 14, 2020	BUY	$12.39 - $17.33 $1.08 Million - $1.51 Million	86,965 New	86,965 $1.49 Million

102

21.5M

50K

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $14M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.